Austco Healthcare Limited Overview
Austco Healthcare is a Melbourne-headquartered, ASX-listed micro-cap that designs, manufactures, installs and maintains clinical communications systems — principally nurse call, mobile clinical messaging, clinical workflow, real-time location services (RTLS) and enterprise reporting — for hospitals and aged-care facilities. Its proprietary Tacera IP nurse call platform, supported by the Medicom range and the Pulse software suite (Pulse Mobile, Pulse Insights, Pulse Manage), sits at the bedside-to-command-centre layer of a facility's digital infrastructure. With FY26 revenue of A$94.2m, EBITDA of A$14.9m and NPAT of A$9.0m, Austco is a small but profitable, debt-free specialist competing against much larger diversified medtech and communications vendors. Since 2023 it has executed a disciplined "buy-your-reseller" roll-up (Teknocorp, Amentco, G&S Technologies, Medical Communications Systems) at a consistent 3.5x normalised EBITDA, converting channel partners into direct sales and installation capability, while seeking to lift the share of higher-margin software and maintenance revenue from an installed base of more than 5,000 facilities.
Company's own description
In its FY26 Directors' Report, Austco describes its principal activities as (i) development of software and manufacture of hardware relating to healthcare and electronic communications systems; (ii) global marketing and sales of electronic healthcare communication systems to established and new customers; and (iii) installation of its own developed and manufactured electronic healthcare communication systems together with third-party sourced complementary low-voltage systems, including access control and security systems (FY26 Appendix 4E, Directors' Report, "Principal Activities"). The company styles itself a "global leader in clinical communications solutions" in its results releases.
The FY26 Investor Presentation frames the portfolio as spanning communication (Tacera and Medicom), workflow optimisation (Pulse Mobile), real-time location services and enterprise reporting, installed together with surrounding low-voltage infrastructure. It maps its role in a facility in four layers: the bedside (call points, in-room devices, RTLS components), the ward (alerts, notifications, mobile applications, touchscreens and displays routing calls to the right clinician), facility-wide software (Tacera handling alarm management, call routing, audio communications and third-party clinical system data) and the command centre (enterprise reporting, operational insight, system readiness monitoring and fall detection).
Business model
Management describes a three-stage model: bid and win, install, and service and extend (FY26 Investor Presentation, "The Austco Healthcare business model"). Clinical communications is typically specified into a building at design stage — often years before construction — and tendered as part of the build programme. An award enters Unfilled Contracted Revenue (UCR) at signing and converts to revenue as equipment is delivered and installation is completed, with a software maintenance agreement (SMA) following commissioning. Once installed, a system's life is measured in decades, giving Austco an annuity opportunity for software upgrades, maintenance and additional modules from a customer already won.
Revenue model
| Revenue line (FY26) | AUD Mn | % of group | YoY growth | Recognition basis | Source |
|---|---|---|---|---|---|
| Equipment | 51.9 | 55% | +12.1% | Point in time, on transfer of control | FY26 Note 2(b); Investor Presentation |
| Installation | 31.0 | 33% | +21.4% | Over time, as performance obligation satisfied | FY26 Note 2(b) |
| Software & SMA | 11.4 | 12% | +19% | Perpetual licences at point of sale (A$5.1m); SMAs and term licences over 1–5 year term (A$6.3m) | FY26 Note 2(b); Directors' Report |
| Total | 94.2 | 100% | +15.8% | — | — |
The model is therefore predominantly product and project-based (88% equipment plus installation), with a recurring layer (SMA and term licences) of roughly 6.7% of revenue recognised over time and a perpetual-licence software layer of roughly 5.4%. There is no material subscription/SaaS revenue disclosed separately; licensing is primarily perpetual.
Value-chain position
Austco is vertically integrated across design (US software development centre and Australian engineering), hardware manufacture (via contract and own assembly — the company references "alternative assembly and distribution models" in its supply-chain risk disclosure), go-to-market (direct in six countries, plus a global network of certified resellers and partners), installation (now substantially in-house in Australia and New Zealand following the four reseller acquisitions) and lifecycle maintenance. The North America segment acts as the product and development hub, recording A$13.0m of intersegment sales to other regions in FY26 (FY26 Note 5).
Customer types and end-markets
Customers are public and private acute hospitals, community hospitals, long-term care and residential aged-care operators, and mental health and rehabilitation facilities. Named reference customers disclosed in FY25–FY26 include Ng Teng Fong General Hospital and Jurong Community Hospital (Singapore), Hospital Israelita Albert Einstein (São Paulo, Brazil), Warrnambool Base Hospital (Victoria), North York General Hospital long-term care (Canada), Toronto Western Hospital (Canada), Angeles Health (Mexico) and the company's unnamed "largest US customer", which is rolling out Pulse Mobile across about 180 hospitals.
Independent characterisation
Austco is best understood as a niche hardware-plus-software clinical communications OEM that is converting itself into a vertically integrated systems integrator in Australasia, while remaining a channel-led OEM in North America, Asia, Europe and Latin America. Its economic engine is the project tender; its strategic prize is the installed base. The acquisitions have lifted revenue but also raised the proportion of lower-margin installation work and third-party low-voltage systems, so headline growth has outpaced the growth of the software layer. The investment case rests on whether the company can (a) keep winning projects in a market dominated by much larger players, (b) monetise its base through SMAs (the July 2026 ten-year Jurong SMA is the template) and Pulse software, and (c) extract operating leverage as acquired cost bases annualise.
Strategy
Stated strategy themes (FY26 Investor Presentation, "Strategy and outlook")
Management articulates five priorities, paraphrased:
-
Continuous innovation — A$4.8m invested in the Tacera platform in FY26, with an AI roadmap extending across predictive care, workflow and system health.
-
Expand recurring revenue — software and maintenance up 19% to A$11.4m (12.0% of revenue), anchored by the ten-year, A$4.2m Jurong SMA.
-
Enhance margin profile — gross margin up 140bp to 53.4% via integration-driven supply-chain efficiencies; operating leverage expected as acquired cost bases annualise.
-
Disciplined and selective M&A — four reseller acquisitions in three years at conservative multiples, each with a performance-based earn-out.
-
Deepen market presence — flagship reference sites in every region (Einstein in Latin America, Jurong in Asia, national ANZ coverage).
The 2025 AGM presentation framed Austco as positioned to target 10–14% organic revenue growth, supported by healthcare megatrends (ageing populations, healthcare digitalisation, regulatory and compliance demands, workforce shortages).
Initiatives announced in the last 24 months
| Date | Initiative | Category | Detail / target | Source |
|---|---|---|---|---|
| Apr–May 2025 | Acquisition of G&S Technologies | Inorganic growth / direct sales | NZ$22.9m revenue, NZ$2.9m EBITDA; 3.5x EBITDA | ASX term sheet (9 Apr 2025) |
| 1 Apr 2025 | Largest SMA contract in company history | Recurring revenue | — | Halo announcement feed |
| FY26 | Integration programme across Teknocorp, Amentco, G&S | Cost / margin | Supply-chain efficiencies; gross margin to 53.4% | FY26 Directors' Report |
| FY26 | Tariff mitigation strategy | Cost / risk | Sourcing, country of origin and pricing review | FY26 Material Business Risks |
| FY26 | Cyber uplift to ACSC Essential Eight | Risk / governance | Underway, with penetration testing | FY26 Material Business Risks |
| Jun 2026 | Pulse Mobile US rollout | Platform / recurring | ~180 hospitals of largest US customer during calendar 2026 | FY26 Trading Update |
| Jul 2026 | Ten-year Jurong SMA | Recurring revenue | A$4.2m, 1 Oct 2026–30 Sep 2036 | ASX (24 Jul 2026) |
| Aug 2026 | MCS acquisition | Inorganic growth | +A$1.88m net revenue, +A$0.82m EBITDA (FY basis) | ASX (10 Aug 2026) |
| Aug 2026 | AI roadmap | Innovation | Predictive intelligence, workflow optimisation, analytics, predictive maintenance | FY26 Investor Presentation |
| FY27 | Formal succession planning programme | Governance | Endorsed by Nomination & Remuneration Committee | FY26 Directors' Report |
ESG/sustainability commitments
No emissions targets, net-zero commitments or sustainability-linked financing have been disclosed. The company states its operations are not significantly affected by Australian environmental regulation (FY26 Directors' Report).
Medium-term targets and guidance
| Item | Guidance | Outcome | Source |
|---|---|---|---|
| FY26 organic revenue growth | 10–14% (Oct 2025) | Not separately reported; total growth 15.8% including G&S annualisation | Q1 FY26 Trading Update |
| FY26 revenue | A$90–95m (Jun 2026) | A$94.2m (top half) | FY26 Trading Update; Appendix 4E |
| FY26 EBITDA | A$14.0–14.6m (Jun 2026) | A$14.8m (above range) | As above |
| FY26 NPAT | A$9.0–9.4m | A$9.0m (bottom of range) | As above |
| FY26 gross margin | ~52.8% | 53.4% | As above |
| FY26 EBITDA margin | ~15.5% | 15.8% | As above |
| FY27 | No quantitative guidance; "healthy sales pipeline, momentum across all regions" and A$51.2m UCR | — | FY26 Investor Presentation |
Products & Services
Austco does not disclose product-level revenue or pricing. The catalogue below is compiled from the FY26 Investor Presentation, ASX releases and company descriptions reproduced by data providers. Products are sold across all geographic segments.
Nurse call and clinical communications platforms
| Product | Description and capabilities | Target customer | Launch / latest | Pricing | Flagship references |
|---|---|---|---|---|---|
| Tacera | Internet-protocol nurse call and clinical communications platform; every component IP-configurable with its own address, enabling system supervision; handles alarm management, call routing, audio communications and integration of information from third-party clinical systems | Acute hospitals, large aged care | Developed late 2000s; commercially deployed by c. 2011–12 (Fiona Stanley, Canberra Hospital, HealthSouth); continuously developed (A$4.8m invested in FY26) | Project-priced; perpetual software licence plus SMA; not disclosed | Ng Teng Fong GH & Jurong CH (Singapore); Hospital Israelita Albert Einstein (Brazil); Warrnambool Base Hospital (VIC) |
| Tacera hardware family | Pendants, pillow speakers, patient call points, pull cords, bathroom call points, annunciators, over-door lights, touchscreen nurse stations, audio devices, in-room devices | As above | Ongoing | Per-device, project-priced | Einstein retrofit: 550 patient stations, 560 over-door lights, >1,000 bathroom call points, 33 nurse stations/annunciators |
| Medicom | Lower-cost nurse call system positioned as a cost-effective alternative to Tacera | Aged care, smaller facilities, budget-constrained buyers | — | — | — |
Mobile, workflow and analytics software (Pulse suite)
| Product | Description and capabilities | Target customer | Launch / latest | Pricing | Notes |
|---|---|---|---|---|---|
| Pulse Mobile | Native iOS/Android application allowing clinical staff to receive and manage nurse call alarms on the move and trigger workflows remotely | Hospitals seeking clinical mobility | Not disclosed; major US deployment during calendar 2026 | Licence plus SMA; not disclosed | Contracted rollout across ~180 hospitals of largest US customer (FY26 Trading Update) |
| Pulse Insights | Enterprise analytics: response-time analysis, staffing adequacy and compliance-readiness dashboards; foundation for AI-informed analysis of call volume and staffing, unusual call patterns and automatic workflow assignment | Hospital administrators, aged-care operators | Live (FY26) | — | Named in FY26 AI roadmap |
| Pulse Manage | Management and administration module within the Pulse suite (functional detail not separately disclosed) | Facility managers | Live (FY26) | — | Named in FY26 enterprise products slide |
| Pulse Reports / Enterprise Reporting | Enterprise reporting and analytics platform across sites | Multi-site operators | — | — | Described by data providers |
| Clinical Workflow | Enables staff to communicate with ancillary departments, measure adherence to protocol and control other systems | Hospitals | — | — | — |
| System Readiness monitoring | Monitors network, servers, device faults and database storage to assure system availability | All installed sites | Live (FY26) | Typically bundled with SMA (not disclosed) | Supports SMA value proposition |
Location, safety and sensing
| Product | Description | Target customer | Status |
|---|---|---|---|
| Built-in RTLS | Real-time location services embedded in the nurse call platform, identifying who is calling and where; staff and patient location components | Hospitals, aged care | Live |
| Fall detection and movement | Radar- or camera-based detection intended, over time, to anticipate resident needs rather than only respond | Aged care, mental health | Live/roll-out (FY26 Presentation) |
Services
| Service | Description | Revenue line |
|---|---|---|
| Installation and integration | Configuration and integration of Austco systems and surrounding low-voltage infrastructure; integration with third-party clinical systems | Installation (A$31.0m FY26) |
| Low-voltage and security systems | Third-party access control, security and related systems installed by acquired integrators (Teknocorp, Amentco, G&S, MCS) | Equipment and installation |
| Software Maintenance Agreements | One- to five-year maintenance agreements (now including a ten-year SMA at Jurong) | Software & SMA |
| Warranty | One- to five-year product warranties (provision A$0.32m at 30 Jun 2026) | Cost provision |
AI roadmap (announced, not yet separately monetised)
The FY26 Investor Presentation sets out four AI layers across Tacera, Pulse and RTLS: (1) predictive clinical intelligence — fall-risk scoring, call-anomaly detection and deterioration early warning from call data and RTLS positioning; (2) intelligent workflow optimisation — AI-based staff routing by acuity, workload, proximity and skill; (3) operational analytics and decision support — foundations live in Pulse Insights; (4) predictive maintenance and system health — AI monitoring of installed hardware to flag device issues before downtime. No launch dates, pricing or revenue targets were disclosed.
Financial Narrative
All figures A$m unless stated; fiscal years ending 30 June. Sources: FY26 Appendix 4E (including five-year performance table in the Remuneration Report); FY25 Results Media Release; FY23 and FY22 Results Releases.
Income statement — five-year
FY22 software/SMA derived from 14.4% of A$35.9m; FY23 from 20.2% of A$42.0m (FY23 Results Release). FY24 share (16.0%) analyst-calculated. Revenue CAGR FY22–FY26: 27.3%; NPAT CAGR FY22–FY26: 40.2% (analyst-calculated).
Source conflict: An InvestSMART AI-generated summary attached to the FY23 annual report link cites FY23 revenue of A$40.9m, a 30.5% increase and NPAT of A$3.2m. These figures conflict with the company's own FY23 release (A$42.0m, +17%, NPAT A$2.26m) and with the five-year table in the FY26 Remuneration Report (A$41.978m, NPAT A$2.258m). The primary-source figures are used.
Income statement — three-year detail
Sources: FY26 Appendix 4E; FY25 Results Release (FY24 gross profit derived as FY25 gross profit A$42.4m less A$11.7m increase). FY23 NPBT was A$1.8m (FY25 Results Release). Note: the company reports FY26 EBITDA as A$14.849m, rounded to A$14.9m in commentary.
Commentary — growth and margins. Revenue nearly tripled between FY22 and FY26. The inflection came in FY24–FY25, driven by acquisitions: Teknocorp (completed November 2023) contributed about A$6.5m and Amentco (May 2024) about A$2.7m in FY24 according to an independent analyst reconciliation, while FY25 benefited from full-year Amentco and one month of G&S. Organic growth in FY25 was roughly 17% (about A$7m), concentrated in North America and Asia (Strawman analyst summary of the FY25 result — secondary source). FY26 growth of 15.8% was more balanced, but the half-year split is critical: 1H26 grew 30.7% while 2H26 grew only 3.4% to A$46.0m, reflecting lumpy project timing, slower construction programmes and tighter hospital capital budgeting.
Gross margin has been remarkably stable in a 52–53.5% band despite a mix shift towards installation; the FY26 improvement to 53.4% came from lower absolute material costs, supply-chain efficiencies through integration and tariff mitigation. EBITDA margin expanded from 13.8% (FY24) to 16.0% (FY25) then eased slightly to 15.8% as overheads grew 22–24% — faster than revenue — with a full year of G&S costs and investment in people. Overheads rose to 42.4% of revenue in FY26 from 40.0% in FY25.
Commentary — earnings quality. Statutory NPAT is noisy. FY24 was flattered by a A$1.4m tax credit on recognition of tax assets; FY25 was depressed by a non-deductible A$2.2m contingent consideration expense (Amentco earn-out outperformance); FY26 was flattered by a non-assessable A$0.9m benefit from a downward revision to the G&S earn-out. On management's underlying basis, NPAT was flat at A$8.1m in both FY25 and FY26 — the single most important nuance for investors and a key reason the share price fell after the June 2026 trading update despite the headline 52% NPAT increase.
Balance sheet
Sources: FY26 Statement of Financial Position and Statement of Changes in Equity (FY24 equity = opening balance at 1 July 2024; FY24 cash = opening cash in FY25 cash-flow statement). FY26 goodwill unchanged because MCS completed after balance date.
Commentary. Austco has no bank debt; "short-term borrowings" of A$0.14m are immaterial. The main quasi-debt items are leases (A$3.8m) and contingent consideration, which fell from A$12.8m to A$2.5m after the A$6.0m cash settlement of the Amentco earn-out (part of which appears to have been settled in shares — contributed equity rose A$3.59m in FY26 with negligible cash proceeds) and the downward revision of the G&S earn-out. The remaining G&S earn-out of A$2.5m is due in March 2027; the MCS earn-out (estimated A$0.64m) is payable after the FY27 audit. Goodwill and intangibles (A$28.2m) represent 45% of equity, typical for a roll-up. Contract liabilities (customer prepayments) fell from A$6.4m to A$3.8m, a modest working-capital headwind and consistent with fewer up-front billings on new projects in 2H26.
Cash flow
Source: FY26 Consolidated Statement of Cash Flows; FCF and conversion analyst-calculated.
Commentary. Cash generation is solid and has funded four acquisitions without debt or a cash equity raise. FY26 cash conversion fell to 84% of EBITDA as inventory rose A$2.0m and contract liabilities unwound, partly offset by lower receivables. 1H26 operating cash flow of A$9.2m effectively matched 1H EBITDA of A$8.3m (1H26 release), implying a weaker 2H26 cash performance.
Ratios
All ratios analyst-calculated from FY26 statements. ROIC uses EBIT x (1 – 22.3% effective tax) over equity plus borrowings plus leases less cash at 30 Jun 2026. Working-capital days use year-end balances against revenue (DSO) and materials & direct labour (DIO, DPO); payables include all trade and other payables, so DPO is overstated relative to pure trade creditors. Negative net debt/EBITDA indicates net cash.
Commentary. Returns are healthy for an industrial technology micro-cap and improving, aided by acquisitions bought at low multiples (3.5x EBITDA implies a pre-tax return on purchase price above 25% before integration costs). Liquidity improved markedly in FY26 as the Amentco earn-out was paid and current contingent liabilities fell. Working capital is the main capital consumer: the business must carry inventory for long-cycle projects and extend credit to public health customers.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from customers (AUD Mn) | 35.9 | 42.0 | 58.2 | 81.4 | 94.2 |
Revenue growth (%) | 15 | 17 | 39 | 40 | 15.8 |
Software & SMA revenue (AUD Mn) | 5.2 | 8.5 | 9.3 | 9.6 | 11.4 |
Software & SMA share of revenue (%) | 14.4 | 20.2 | 16.0 | 11.7 | 12.0 |
Net profit after tax (AUD Mn) | 2.33 | 2.26 | 7.08 | 5.93 | 9.01 |
Net margin (%) | 6.5 | 5.4 | 12.2 | 7.3 | 9.6 |
Basic EPS (A cents) | 0.82 | 0.78 | 2.33 | 1.63 | 2.41 |
Dividends paid per share (A cents) | 0 | 0.475 | 0 | 0 | 0 |
Year-end share price (AUD) | 0.10 | 0.17 | 0.18 | 0.29 | 0.25 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (FY2024–FY2026)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Revenue (AUD Mn) | 58.2 | 81.4 | 94.2 |
Gross profit (AUD Mn) | 30.7 | 42.4 | 50.3 |
Gross margin (%) | 52.8 | 52.0 | 53.4 |
Overhead cost base excl. D&A (AUD Mn) | 25.0 | 32.6 | 39.9 |
EBITDA (AUD Mn) | 8.1 | 13.0 | 14.8 |
EBITDA margin (%) | 13.8 | 16.0 | 15.8 |
Depreciation & amortisation (AUD Mn) | — | 2.9 | 4.0 |
EBIT (AUD Mn) | — | 10.2 | 10.9 |
Contingent consideration (expense)/benefit (AUD Mn) | 0 | -2.2 | 0.9 |
Profit before tax (AUD Mn) | 5.7 | 8.1 | 11.6 |
Income tax expense (AUD Mn) | — | 2.1 | 2.6 |
Effective tax rate (%) | not meaningful (A$1.4m tax credit) | 26.4 | 22.3 |
NPAT (AUD Mn) | 7.1 | 5.9 | 9.0 |
Underlying NPBT excl. contingent consideration (AUD Mn) | — | 10.3 | 10.7 |
Underlying NPAT excl. contingent consideration (AUD Mn) | — | 8.1 | 8.1 |
Diluted EPS (A cents) | — | 1.60 | 2.38 |
“—” = not publicly disclosed.
Balance Sheet and Per-Share Data
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Cash and equivalents (AUD Mn) | 13.6 | 14.5 | 16.3 |
Trade and other receivables (AUD Mn) | — | 21.7 | 18.2 |
Inventories (AUD Mn) | — | 9.3 | 11.3 |
Total current assets (AUD Mn) | — | 51.6 | 50.3 |
Goodwill (AUD Mn) | — | 21.4 | 21.4 |
Capitalised development & other intangibles (AUD Mn) | — | 6.8 | 6.8 |
Total assets (AUD Mn) | — | 91.1 | 88.5 |
Short-term borrowings (AUD Mn) | — | 0.16 | 0.14 |
Long-term borrowings (AUD Mn) | 0 | 0 | 0 |
Lease liabilities, total (AUD Mn) | — | 3.7 | 3.8 |
Contingent consideration liabilities (AUD Mn) | — | 12.8 | 2.5 |
Contract liabilities (AUD Mn) | — | 6.4 | 3.8 |
Total liabilities (AUD Mn) | — | 39.3 | 26.4 |
Total equity (AUD Mn) | 44.4 | 51.7 | 62.1 |
Net cash excl. leases (AUD Mn) | — | 14.3 | 16.1 |
Net cash incl. leases (AUD Mn) | — | 10.6 | 12.3 |
Working capital, current assets less current liabilities (AUD Mn) | — | 18.4 | 26.8 |
NTA per share incl. ROU (A cents) | — | 5.42 | 8.24 |
“—” = not publicly disclosed.
Cash Flow and Margin Analysis (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
Operating cash flow (AUD Mn) | 13.4 | 12.5 |
Capex — plant & equipment (AUD Mn) | 2.8 | 0.8 |
Capitalised development / intangibles (AUD Mn) | 2.0 | 2.0 |
Free cash flow, OCF less capex and capitalised development (AUD Mn) | 8.7 | 9.7 |
Lease principal payments (AUD Mn) | 0.8 | 1.4 |
FCF after leases (AUD Mn) | 7.9 | 8.3 |
Acquisitions net of cash acquired (AUD Mn) | 6.7 | 0 |
Contingent consideration paid (AUD Mn) | 0.8 | 6.0 |
Dividends paid (AUD Mn) | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 |
Net change in cash (AUD Mn) | 0.7 | 2.3 |
OCF / EBITDA conversion (%) | 103 | 84 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | FY2026 |
|---|---|---|
ROE, NPAT / average equity (%) | 12.3 | 15.8 |
ROA, NPAT / average assets (%) | — | 10.0 |
ROIC, NOPAT / invested capital (%) | not calculated | 17.0 |
Current ratio (x) | 1.56 | 2.14 |
Debt / equity incl. leases (%) | 7.5 | 6.4 |
Net debt / EBITDA (x) | -0.8 | -0.8 |
Interest coverage, EBIT / finance costs (x) | 44.4 | 27.9 |
Asset turnover, revenue / average assets (x) | not calculable | 1.05 |
Days sales outstanding (days) | 97 | 70 |
Days inventory outstanding (days) | 87 | 94 |
Days payables outstanding (days) | 116 | 109 |
Cash conversion cycle (days) | 68 | 55 |
Region Overview
| Region | Equipment | Installation | Software/SMA | Total |
|---|---|---|---|---|
Australia/New Zealand | 26.9 | 18.6 | 7.3 | 52.8 |
North America | 19.4 | 9.4 | 1.6 | 30.4 |
Europe | 2.2 | 1.4 | 0.8 | 4.4 |
Asia | 3.3 | 1.7 | 1.7 | 6.7 |
Total | 51.9 | 31.0 | 11.4 | 94.2 |
Australia/New Zealand | 21.3 | 14.0 | 2.9 | 38.2 |
North America | 15.4 | 7.5 | 4.5 | 27.4 |
Europe | 2.6 | 1.7 | 0.6 | 5.0 |
Asia | 6.9 | 2.4 | 1.5 | 10.8 |
Total | 46.3 | 25.6 | 9.6 | 81.4 |
Region revenue (AUD Mn)
| Region revenue (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Australia/New Zealand | 38.2 | 52.8 |
North America | 27.4 | 30.4 |
Asia | 10.8 | 6.7 |
Europe | 5.0 | 4.4 |
Region revenue growth (%) | FY2026 | — |
Australia/New Zealand | 38.1 | — |
North America | 11.0 | — |
Asia | -38.1 | — |
Europe | -12.4 | — |
Region share of revenue (%) | FY2025 | FY2026 |
Australia/New Zealand | 47 | 56 |
North America | 34 | 32 |
Asia | 13 | 7 |
Europe | 6 | 5 |
Revenue by Region
| UCR by region (AUD Mn) | Feb-2026 | Aug-2026 |
|---|---|---|
North America | 24.2 | 24.5 |
Australia/New Zealand | 16.2 | 16.7 |
Asia | 4.8 | 8.0 |
Europe | 2.1 | 1.9 |
Total | 47.2 | 51.2 |
Year-end share price (AUD)
| Year-end share price (AUD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Closing price at 30 June | 0.10 | 0.17 | 0.18 | 0.29 | 0.25 |
Share Price & Returns
| Period | Approximate performance | Basis |
|---|---|---|
1-year (Oct 2025 → Oct 2026) | Approx. -35% to -40% (from c. A$0.41–0.44 around the Oct 2025 AGM to c. A$0.25–0.27) | InvestSMART announcement price records |
3-year (Oct 2023 → Oct 2026) | Approx. +25% to +45% (FY24 trading range A$0.17–0.22) | StockLight 52-week ranges; InvestSMART |
vs S&P/ASX 200 (1-year) | -19.3% relative underperformance (as reported) | Market Index |
52-week range | Approx. A$0.22–0.445 (aggregator data; verify live) | Yahoo Finance (FR); InvestSMART |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Share price | c. A$0.25 | InvestSMART (Oct 2026) |
Shares on issue | c. 375m | Analyst estimate from Simply Wall St ownership breakdown and FY26 EPS denominator (c. 372.5m weighted) |
Market capitalisation | c. A$94m | InvestSMART |
Enterprise value (market cap – cash + borrowings + leases) | c. A$82m | Analyst-calculated from 30 Jun 2026 balance sheet |
P/E (FY26 basic EPS 2.418c) | c. 10.3x | Analyst-calculated |
P/E on underlying NPAT (A$8.1m) | c. 11.6x | Analyst-calculated |
EV/EBITDA (FY26 A$14.8m) | c. 5.5x | Analyst-calculated |
EV/Sales (FY26) | c. 0.87x | Analyst-calculated |
P/B (net assets A$62.1m) | c. 1.5x | Analyst-calculated |
FCF yield (FCF after leases A$8.3m) | c. 8.8% | Analyst-calculated |
Dividends paid per share (A cents)
| Dividends paid per share (A cents) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend | 0 | 0.475 | 0 | 0 | 0 |
Capital Markets
| Item | Status |
|---|---|
Buyback authorisation | None disclosed |
Moody's / S&P / Fitch ratings | Not rated |
Bank debt | None; short-term borrowings A$0.14m |
Lease liabilities | A$1.1m current; A$2.7m non-current (30 Jun 2026) |
Deferred consideration maturities | G&S earn-out A$2.5m due March 2027; MCS earn-out est. A$0.64m after FY27 audit |
Potential dilution | 8,198,754 performance rights on issue (2,730,877 vested on FY26 accounts) |
Analyst Conclusions
Management guidance
Austco has not issued quantitative FY27 guidance. It enters FY27 with a "healthy sales pipeline", momentum across all regions and A$51.2m of UCR at 17 August 2026, up 13% since 30 June 2026 on genuine new order intake (FY26 Investor Presentation and Directors' Report). Management expects integration efficiencies and lower input costs to continue supporting gross margin in FY27, and operating leverage as acquired cost bases annualise. Incremental FY27 contributions are visible from MCS (c. A$1.88m net revenue and A$0.82m EBITDA on a full-year basis, less a partial first year), the Jurong SMA (A$4.2m over ten years, c. A$0.3m in FY27) and the Pulse Mobile rollout.
Consensus expectations
Consensus estimates are not publicly disclosed in sources reviewed. The company's 10–14% organic growth target (stated October 2025) is the best available management anchor.
Bull case
-
Recurring revenue inflection. Software/SMA growth accelerated to 19% in FY26, with 2H revenue 28% above 1H (A$6.4m versus A$5.0m), before the Jurong SMA and full Pulse Mobile deployment. UCR includes A$12.6m of SMA and software. If recurring revenue compounds at 15–20% while project revenue grows high-single digits, mix shift could lift EBITDA margins towards 18–20%.
-
Cheap, cash-generative and debt-free. At c. 5.5x EV/EBITDA and c. 9% FCF yield with net cash, the market prices Austco as an ex-growth hardware installer despite a 27% four-year revenue CAGR and ROIC near 17%.
-
Proven, repeatable M&A. Four deals at 3.5x EBITDA, funded internally, give a self-funding growth engine; national ANZ coverage is now in place and the formula could be exported.
Bear case
-
Underlying earnings have stalled. Underlying NPAT was flat at A$8.1m in FY25 and FY26; overheads grew 24% versus 15.8% revenue growth, and 2H26 revenue grew only 3.4%.
-
Order book not growing. Reported UCR fell from A$55.8m (Jul 2025) to A$51.2m (Aug 2026); even on a constant-currency basis it rose only 1% over 12 months — inconsistent with double-digit organic growth.
-
Structural mix dilution and scale disadvantage. Recurring revenue fell from 20% of revenue (FY23) to 12% (FY26) as installation-heavy acquisitions were added; R&D intensity has fallen to 5.1% while competitors with vastly greater resources invest in AI-enabled clinical communications.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | What to watch |
|---|---|---|
| Late Oct 2026 | 2026 AGM and Q1 FY27 trading update | Q1 revenue growth, UCR trajectory, any FY27 guidance |
| Calendar 2026 | Pulse Mobile rollout across ~180 US hospitals | Deployment progress, recognised software/SMA revenue, follow-on US contracts |
| From 1 Oct 2026 | Jurong ten-year SMA commencement | Recurring revenue build; replication with other installed-base customers |
| FY27 | MCS integration | Accretion versus A$0.82m EBITDA target; earn-out estimate |
| Feb 2027 | 1H27 results | Overhead growth versus revenue; EBITDA margin; software/SMA share |
| March 2027 | G&S earn-out payment (A$2.5m) | Cash outflow; signal of G&S performance |
| By c. Mar 2027 | Einstein Tacera retrofit deliveries | Latin American follow-on wins |
| Ongoing | US tariff regime and AUD/USD | Gross margin and UCR translation |
| Ongoing | Further acquisitions | Discipline on 3.5x multiple; geography of next deal |
| Ongoing | Asia/Europe project conversion | Asia UCR of A$8.0m converting to revenue |
Analyst verdict
Austco Healthcare is a well-run, conservatively financed niche operator whose recent history divides into two chapters. The first, from FY22 to FY25, was a transformation: revenue more than doubled, EBITDA margins expanded from below 14% to 16%, and a disciplined reseller roll-up converted channel partners into a direct ANZ sales and installation platform at uniformly low multiples, funded entirely from cash flow. The second chapter, which began in the second half of FY26, is a test of quality. Headline numbers remain records — A$94.2m revenue, A$14.8m EBITDA, A$9.0m NPAT — but underlying NPAT has been flat for two years, overheads are outrunning revenue, the second half barely grew, and the order book is no larger in constant currency than it was a year earlier. The market has noticed: the shares have roughly halved from their October 2025 peak and now trade at about 5.5x EV/EBITDA and 10x earnings, with net cash.
At that valuation, investors are no longer paying for growth; they are being paid to wait for evidence that the platform strategy is working. The evidence to look for is specific and measurable within twelve months: Pulse Mobile revenue recognised from the 180-hospital US rollout, the Jurong SMA replicated elsewhere in the installed base, software and SMA rising above 13–14% of revenue, and overhead growth falling back below revenue growth as acquired cost bases mature. If those markers appear, Austco's combination of a 5,000-facility installed base, a debt-free balance sheet and a repeatable acquisition engine argues for a materially higher multiple. If they do not, Austco risks being valued as what its revenue mix increasingly resembles — a competent regional installer of hardware, exposed to hospital capital cycles and outscaled by global rivals. On balance, the risk-reward is asymmetric to the upside at current prices, but the thesis is execution-dependent and catalyst-driven rather than self-evident, and position sizing should reflect micro-cap liquidity and project lumpiness.
Analyst-calculated figures are identified as such. Market data (price, market capitalisation, trailing returns) are approximate as of early October 2026 and should be refreshed from a live source.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Education | FY26 total remuneration (AUD) |
|---|---|---|---|---|---|
Clayton Astles | Managing Director / CEO and Executive Director | CEO since July 2015; with Austco since c. 2008 | President, Austco Marketing & Services (USA); over 20 years' healthcare technology leadership | Diploma in Electronics Engineering | 967,004 (salary 560,489; cash bonus 221,282; other 56,707; leave accrual 29,237; performance rights 99,289). Base fixed at US$380,000 since 2015 |
Brendan Maher | CFO, COO ANZ and Company Secretary | Company Secretary since October 2018 | CFO of Adslot; Company Secretary of Skilled Group and Adslot; Arthur Andersen; National Westminster Bank | Chartered Accountant (CA ANZ); GAICD | 540,274 (salary 363,837; bonus 80,000; leave 8,695; rights 57,742; super 30,000) |
Andrew Hall | Chief Commercial Officer | — | — | — | Not a KMP; not disclosed |
Matthew Pearson | Investor Relations | — | — | — | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Appointed | Independence | Committees | Background | FY26 fees (AUD) |
|---|---|---|---|---|---|---|
Graeme Billings | Non-Executive Chairman | October 2015 | Independent (assessed) | Chair, Audit & Risk Management Committee | Chartered Accountant since 1980; 34 years at PwC (former head of Melbourne assurance practice); former Chair of Amotiv Ltd (to Oct 2025) and NED of Clover Corporation (to Nov 2025) | 111,251 |
Brett Burns | Non-Executive Director | October 2015 | Board assesses as independent; note related-party legal (A$67k) and IR (A$60k via Pont Equity) fees | Chair, Nomination & Remuneration Committee | Managing Partner, CBW Partners (corporate law); former Company Secretary and General Counsel of an ASX top-20 company; former ASIC regulator; GAICD | 86,500 |
Anthony Glenning | Non-Executive Director | September 2018 | Independent | Member of both committees | Founder of Tonic Systems (sold to Google 2007); Starfish Ventures Investment Director 2010–2018; Fund Advisor, Skalata Ventures; NED of Pro Medicus and Iress; BEng (Elec), BCompSc (Melbourne), MSEE (Stanford) | 79,000 |
Ann Larkins | Non-Executive Director | — | Independent | Member of both committees | Executive Director and CIO, Australian Red Cross Lifeblood; former Executive Director/CIO roles at Barwon Health and Alfred Health; critical care nursing background; Master of Business Technology (UNSW); Certified Healthcare CIO (CHIME); GAICD | 79,000 |
Clayton Astles | Executive Director | July 2015 | Not independent | Attends committees | See above | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
FY25 (c. early 2025) | Ann Larkins joins the Board | Adds health-IT and clinical expertise |
October 2025 | Graeme Billings steps down from Amotiv board | Reduces external commitments |
November 2025 | Graeme Billings steps down from Clover Corporation board | As above |
FY27 | Formal succession planning programme being rolled out | Disclosed as a mitigation of key-person risk (FY26 Material Business Risks) |
Major Shareholders
| Holder | Shares | Stake (%) | Date of last notice | Source |
|---|---|---|---|---|
Asia Pac Technology Pty Ltd | 54,777,798 | 14.62 | 30 Sep 2025 | Market Index (substantial holder notices) |
Australian Ethical Investment Ltd | 51,201,161 | 14.06 | 22 Aug 2025 (reduced from 15.59%) | Market Index; TipRanks |
Clayton Astles (CEO) | 4,163,035 plus 2,131,874 performance rights | c. 1.1 | 30 Jun 2026 | FY26 Remuneration Report |
Brendan Maher (CFO) | 2,427,162 | c. 0.6 | 30 Jun 2026 | FY26 Remuneration Report |
Brett Burns | 1,497,504 | c. 0.4 | 30 Jun 2026 | FY26 Remuneration Report |
Anthony Glenning | 1,058,870 | c. 0.3 | 30 Jun 2026 | FY26 Remuneration Report |
Graeme Billings | 530,776 | c. 0.1 | 30 Jun 2026 | FY26 Remuneration Report |
Competitive Landscape
Key Competitors
| Competitor | Parent / ownership | Primary overlap | Geography of overlap | Relative positioning vs Austco | Revenue (comparable segment) |
|---|---|---|---|---|---|
Rauland (Responder nurse call) | AMETEK Inc. | Nurse call, clinical workflow | North America, ANZ, Middle East | Market leader in US nurse call; far larger scale | Not separately disclosed by parent |
Hillrom (Voalte, NaviCare nurse call) | Baxter International | Nurse call, mobile communications, care coordination | North America, global | Integrated with beds/devices; much broader portfolio | Not separately disclosed at product level |
Ascom | Ascom Holding AG (SIX-listed) | Nurse call (telligence, teleCARE), mobile messaging, alarm management | Europe, ANZ, North America | Strongest European incumbent; broader mobile workflow | — |
Vocera | Stryker Corporation | Clinical communications, wearable badges, mobile messaging | North America, ANZ, UK | Leader in mobile clinical comms; overlaps with Pulse Mobile | Not separately disclosed by parent |
Jeron Electronic Systems | Private | Nurse call (Provider) | North America | Mid-market US specialist | — |
Spok | Spok Holdings (NASDAQ: SPOK) | Clinical communications, paging, alarm management | North America | Software-centric; complements or substitutes Pulse | — |
Cornell Communications | Private | Nurse call (aged care focus) | North America | Lower-cost aged-care competitor | — |
TekTone | Private | Nurse call | North America | Value-segment competitor | — |
Critical Alert | Private | Nurse call and clinical workflow | North America | Software-led US competitor | — |
Courtney Thorne / Static Systems / Intercall | Private UK specialists | Nurse call | UK | Local incumbents in UK NHS and care homes | — |
Local integrators and Ascom/Rauland resellers | Various | Installation and low-voltage integration | ANZ | Compete for installation scopes Austco now self-performs | — |
“—” = not publicly disclosed.
Competitor Detail
| Metric | Austco (FY26) |
|---|---|
Revenue | A$94.2m |
Revenue growth | 15.8% |
Gross margin | 53.4% |
EBITDA margin | 15.8% |
R&D intensity | 5.1% |
Recent Developments
A 2026 AGM (typically late October) and Q1 FY27 trading update are expected but had not been released as at the research cut-off.*



